You can switch from a full-dose GLP-1 to a microdose only if a licensed provider decides that is right for you, and research on the move is limited. Microdosing is not an FDA-approved schedule. The nearest evidence is a 2026 tirzepatide trial, in which people stepping down to an approved 5 mg dose had a 16.6% weight loss at week 112, against 21.9% for those staying on their dose.
Five milligrams is not a microdose, and that distinction shapes this whole subject. The Zepbound label approves 5 mg as a maintenance dose. Wegovy’s label allows 1.7 mg as well as 2.4 mg for weight reduction. So a person who wants to take less may have a labeled step down available before anyone leaves the schedule.
Yale Medicine makes a related point. Some people respond strongly at the lowest approved dose, and a Yale specialist sees no reason to raise the dose for them. That is a clinical judgment about one person, and it stays inside the labeled range.
What happens when you step down from a full GLP-1 dose?
SURMOUNT-MAINTAIN is the best study so far. It was published in The Lancet and funded by Eli Lilly. After 60 weeks on 10 mg or 15 mg of tirzepatide, 378 adults with obesity were split into three groups for another year: stay on the dose, drop to 5 mg, or switch to placebo. Those on placebo ended 9.9% below their starting weight, on the model-based estimate, and the 5 mg group sat between the other two. Rescue treatment for regaining at least half the lost weight went to 8% of those who stayed on, 25% at 5 mg and 67% on placebo.
The authors wrote that 5 mg might be a useful alternative to stopping, and that response varies by person. They also wrote that long-term treatment is often needed. Those findings came from an approved dose in a controlled trial. They do not transfer to doses below the label or to a compounded product.
Coming off altogether is better studied, and it is sobering. In the STEP 1 extension, people who stopped semaglutide 2.4 mg regained about two-thirds of their earlier loss within a year. In SURMOUNT-4, those moved to placebo regained 14.0% from week 36 to week 88, while those who stayed on tirzepatide lost a further 5.5%. Where a microdose lands on that range is unknown, and we found no study that measured it.
How does the switch itself work?
There is no labeled method, because microdosing is not on the label. A provider has to decide how far to drop, how fast, and what to watch. Weight, appetite, side effects and labs are the obvious things. Any change also runs into the drug’s slow clearance. The Wegovy label says semaglutide stays in circulation for about 5 to 7 weeks after a last dose, so the first few weeks after a change can be misleading. Early calm may just be old drug still working.
Do not try this at home with a pen. A 2026 commentary describes click counting, which means trying to measure partial doses from multidose pens, and it raises concerns about dose accuracy. A review summarized by News-Medical raises sterility questions about splitting doses from existing devices. Both brand labels say pens must never be shared.
Moving from a brand pen to a compounded vial adds a change of its own. It means a different product, a syringe and new math. Compounded drugs are not FDA-approved, and they are not a version of the brand you were using. The FDA has reports that may be tied to dosing errors with compounded injectable semaglutide, including wrong amounts measured by patients. Some medications prescribed through Living+ are compounded.
Restarting has rules too. The Wegovy label says that after 2 or more missed doses in a row, treatment should restart escalation at a lower dose. Skipped weeks are not a harmless way to test a lower exposure. Stretching the gap on your own also makes it hard for a provider to know what you are really taking.
At Living+, a licensed provider reviews your history and current medicines, and may decide against the switch. Bring one question to that visit: what the plan is if the weight starts coming back. That is the outcome the trials above measured most closely.
Quick answers
Can I just lower my GLP-1 dose on my own?
No. Dose changes should go through a licensed provider, who can review your history and watch what happens. Measuring partial doses from a pen raises accuracy and sterility concerns, and the FDA has reports that may be tied to dosing errors.
Will I regain weight if I switch to a microdose?
No one knows for microdoses, since research is limited. In a 2026 tirzepatide trial, people who dropped to an approved 5 mg dose kept less of their weight change than those who stayed on their full dose. They kept more than those switched to placebo.
Is stepping down to a lower approved dose the same as microdosing?
No. The Zepbound label approves 5 mg for maintenance, and the Wegovy label allows 1.7 mg for weight reduction. Doses below the labeled schedule are a different matter, and microdosing is not an FDA-approved dosing schedule.
Can I move from a brand pen to a compounded microdose?
Only if a licensed provider decides to prescribe it, and they may decide no. Compounded drugs are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound or Mounjaro. They also usually mean measuring doses with a syringe, which leaves more room for error.
Sources
- Horn et al., SURMOUNT-MAINTAIN, The Lancet 2026
- Aronne et al., SURMOUNT-4 randomized clinical trial, JAMA 2024
- Wilding et al., Weight regain after withdrawal of semaglutide, STEP 1 extension, Diabetes Obes Metab 2022
- DailyMed: Wegovy prescribing information
- DailyMed: Zepbound prescribing information
- Beck and Clements, Considerations and challenges in microdosing of GLP-1-based receptor agonists, Expert Opin Pharmacother 2026
- FDA: FDA's concerns with unapproved GLP-1 drugs used for weight loss
- FDA: Compounding and the FDA, questions and answers
- Yale Medicine: Microdosing GLP-1 and Accutane, what does it mean and does it work
- News-Medical: GLP-1 drugs have benefits beyond weight loss. Could microdoses preserve them?
See what a Living+ plan costs and whether it fits.
Wegovy is a registered trademark of Novo Nordisk A/S. Zepbound is a registered trademark of Eli Lilly and Company. Living+ is not affiliated with or endorsed by these companies.
